Wall Street Is Betting Big on Psychedelic Therapy — Here's What It Means for Ketamine Patients
Something remarkable happened this week: Deutsche Bank, one of the world's largest financial institutions, issued a buy rating on psychedelic therapy companies, calling the current moment a "Psychedelic Renaissance." They set a price target that implies a 250%+ gain for the sector.
This isn't fringe science anymore. When Wall Street puts real money behind psychedelic-assisted mental health treatment, it signals that the mainstream medical establishment is catching up to what patients have known for years: ketamine therapy works.
Why Wall Street Is Paying Attention Now
Several converging factors have made 2026 a tipping point for psychedelic therapy:
Considering at-home ketamine therapy?
Kalm offers guided at-home ketamine treatment starting at $124/month — no clinic visits required. Start your assessment →
-
Clinical data keeps stacking up: The Nature Mental Health randomized controlled trial on ketamine-assisted therapy for opioid use disorder showed significant reductions in drug use and cravings with zero serious adverse events
-
FDA is opening doors: Expanded access for NRX-100 (preservative-free ketamine) for suicidal ideation was granted in March 2026
-
Scientific breakthroughs: Researchers just discovered how to potentially make ketamine's antidepressant effects last longer by targeting the NOX-1 enzyme
-
Mainstream cultural acceptance: Ketamine therapy has been covered in major outlets — from congressional spending disclosures to Psychiatric Times features on ketamine-assisted psychotherapy
What This Means for People Considering Ketamine Therapy
Wall Street's investment thesis is simple: mental health treatment is evolving, and psychedelic-assisted therapies like ketamine are leading the way. For patients, this means:
More Research, Better Treatments
As investment flows into the sector, clinical trials accelerate. AtaiBeckley alone has two major Phase 2 data readouts expected in the second half of 2026. Every new study helps us understand how to optimize ketamine therapy for better, longer-lasting results.
Growing Legitimacy
When institutions like Deutsche Bank back psychedelic therapy, it breaks down stigma. More doctors become open to prescribing it. More patients feel comfortable trying it. The virtuous cycle continues.
Ketamine Remains the Most Accessible Option
While psilocybin programs are still limited to Oregon and Colorado, and MDMA-assisted therapy awaits FDA approval, ketamine is the only psychedelic-adjacent treatment available nationwide right now. You don't need to wait for regulatory approvals or travel to a special clinic.
How to Access Ketamine Therapy Today
Kalm makes it simple to start at-home ketamine therapy with full medical supervision:
- Complete your online evaluation with a licensed provider
- Receive your personalized treatment protocol
- Begin therapy at home with ongoing medical support
Our program is available in all 50 states at just $124/month. Most patients report feeling significantly better within 5 days, and we offer a price-match guarantee — we'll beat any competitor's price by 20%.
The Bigger Picture: Ketamine in 2026
The convergence of Wall Street investment, breakthrough research, and growing public acceptance makes this a transformative year for mental health treatment. Here's what's on the horizon:
-
NRX-100 expanded access for suicidal ideation is already underway
-
NOX-1 research could eventually lead to longer-lasting ketamine effects
-
Ketamine-assisted psychotherapy (KAP) is gaining formal recognition for trauma and PTSD
-
New Mexico's medical psilocybin program is expected to enroll first patients by end of 2026 — but ketamine remains years ahead in accessibility
Frequently Asked Questions
Why is Wall Street investing in psychedelic therapy?
Deutsche Bank and other financial institutions see the clinical evidence supporting ketamine and other psychedelic-assisted therapies as a major growth opportunity. The mental health treatment market is evolving rapidly, and psychedelic therapies are at the forefront.
Is ketamine considered a psychedelic?
Ketamine is often described as psychedelic-adjacent. While it can produce dissociative effects at certain doses, its primary therapeutic use is as a rapid-acting antidepressant. It is the most accessible psychedelic-related treatment in the US today.
How is at-home ketamine therapy different from clinic-based treatment?
At-home ketamine therapy through Kalm is medically supervised via telehealth, more affordable than clinic visits, and available in all 50 states. You receive treatment in the comfort of your home while maintaining contact with your care team.
How much does ketamine therapy cost?
Kalm offers at-home ketamine therapy starting at $124/month with a price-match guarantee. This is significantly less than clinic-based IV ketamine infusions, which typically cost $400-800 per session.
Ready to Join the Therapy Revolution?
You don't need to wait for Wall Street to tell you what millions of patients already know. Ketamine therapy can change your life — and you can start from home.
Get started with Kalm today →
Learn more about ketamine therapy: Ready to take the next step? Get started with Kalm today. Explore the Kalm program. For an independent overview of providers, see the Ketamine Providers Guide.
Ready to explore at-home ketamine therapy?
No waiting rooms. No insurance hassles. Treatment guided by licensed providers, from the comfort of home.
Get Started — $124/month →
